Alyeska Investment Group’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Alyeska Investment Group’s Portfolio FSTX Stock Details FSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-50,000	Closed	-$294K	–	620
2020 Q2	$294K	Hold	50,000	–	–	﹤0.01%	453
2020 Q1	$186K	Hold	50,000	–	–	﹤0.01%	355
2019 Q4	$316K	Hold	50,000	–	–	﹤0.01%	371
2019 Q3	$688K	Hold	50,000	–	–	0.01%	343
2019 Q2	$738K	Hold	50,000	–	–	0.01%	384
2019 Q1	$2.1M	Hold	50,000	–	–	0.03%	280
2018 Q4	$2.08M	Hold	50,000	–	–	0.03%	283
2018 Q3	$2.41M	Hold	50,000	–	–	0.03%	290
2018 Q2	$2.37M	Hold	50,000	–	–	0.02%	342
2018 Q1	$3.08M	Hold	50,000	–	–	0.03%	321
2017 Q4	$2.69M	Hold	50,000	–	–	0.02%	309
2017 Q3	$3.37M	Hold	50,000	–	–	0.03%	320
2017 Q2	$2.71M	Hold	50,000	–	–	0.02%	322
2017 Q1	$1.78M	Hold	50,000	–	–	0.01%	404
2016 Q4	$1.6M	Buy	+50,000	New	+$1.83M	0.01%	406

Other funds holding FSTX

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alyeska Investment Group's FSTX Position: Q3 2021 in Review

Alyeska Investment Group sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q3 2021, closing a stake of 150,000 shares — an estimated $1.29M sold.

Alyeska Investment Group first reported a position in FSTX in Q4 2016 and held it in 8 quarters. The position peaked at $6.2M in Q3 2017. 37 funds tracked by Wall St. Rank hold FSTX as of Q3 2021.

Alyeska Investment Group reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Alyeska Investment Group sold 150,000 F-star Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.29M.
Alyeska Investment Group first reported a position in F-star Therapeutics, Inc. Common Stock in Q4 2016 and held it in 8 quarters.
Alyeska Investment Group's F-star Therapeutics, Inc. Common Stock position peaked at $6.2M in Q3 2017.
37 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Alyeska Investment Group's 13F filing for Q3 2021, filed 15 Nov 2021.